BioCentury | Feb 12, 2021
Regulation

FDA approval of Regeneron’s Evkeeza brings new drug class to HoFH patients

...treatment options for those patients. In the Phase III TESLA trial in 49 HoFH patients, Repatha evolocumab...
BioCentury | Dec 12, 2020
Regulation

RNA therapies get another 2020 win with inclisiran approval

...same target —Praluent alirocumab and Repatha evolocumab...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Blocking PCSK9 alone or with anti-PD-1 therapies for cancer

...an anti-PD-1 mAb improved antitumor activity. In the colorectal cancer model, the anti-PCSK9 mAbs Repatha evolocumab...
...tumor size and extended survival, and combining either agent with a PD-1 inhibitor enhanced efficacy. Repatha...
...11, 2020doi:10.1038/s41586-020-2911-7CONTACT: Chuan-Yuan Li, Duke University Medical Center, Durham, N.C.email: chuan.li@duke.edu Claire Quang Repatha (Brand), AMG 145 (Compound #), evolocumab (Generic), Repatha...
BioCentury | Jun 11, 2020
Finance

Insiders lead, crossovers join in gene editing play Verve’s $63M round

...arrival at Verve. Other lipid-lowering approaches involving those targets have included marketed PCSK9 inhibitors Repatha evolocumab...
BioCentury | Feb 22, 2020
Product Development

Esperion enters crowded LDL-lowering market with FDA approval

...price of Nexletol. Competing LDL-C lowering agents Praluent alirocumab from Sanofi (Euronext:SAN; NASDAQ:SNY) and Repatha evolocumab...
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

...at Amgen Inc. (NASDAQ:AMGN), where he was responsible for the development of cardiovascular drug Repatha evolocumab...
BioCentury | Jan 23, 2020
Company News

With established foothold in Japan, Amgen takes over JV from Astellas

...Since then, the partners have launched three Amgen drugs in the country: cholesterol-lowering agent Repatha evolocumab...
BioCentury | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

...U.S. for creating a race to the bottom for Praluent and fellow PCSK9 inhibitor Repatha evolocumab...
BioCentury | Nov 26, 2019
Company News

After mid-decade makeover, Medicines Co. accepts Novartis' $9.7B bid on eve of inclisiran submission

...inclisiran, which prevents translation of the PCKS9 gene, would compete against marketed anti-PCSK9 mAbs Repatha evolocumab...
...2015. Repatha’s sales were about $461 million over the first nine months of 2019, while Repatha’s...
...in the past." Table: Comparing PCSK9 data Selected clinical data from trials of inclisiran, Repatha evolocumab...
BioCentury | Nov 9, 2019
Product Development

Amgen to accelerate China strategy via BeiGene deal

...next year, it plans to launch hypercholesterolemia drug Repatha evolocumab and osteoporosis drug Prolia denosumab. Repatha...
...will focus its own efforts on non-oncology products, where it plans to launch PCSK9 inhibitor Repatha...
...Amgen products in Japan. Amgen owned 51% of the JV. Two of the drugs -- Repatha...
Items per page:
1 - 10 of 300